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Abstract
Treatment effects, especially when comparing two or more therapeutic alternatives as in
comparative effectiveness research, are likely to be heterogeneous across age, gender, co-
morbidities, and co-medications. Propensity scores (PSs), an alternative to multivariable outcome
models to control for measured confounding, have specific advantages in the presence of
heterogeneous treatment effects. Implementing PSs using matching or weighting allows us to
estimate different overall treatment effects in differently defined populations. Heterogeneous
treatment effects can also be due to unmeasured confounding concentrated in those treated
contrary to prediction. Sensitivity analyses based on PSs can help to assess such unmeasured
confounding. PSs should be considered a primary or secondary analytic strategy in non-
experimental medical research, including pharmacoepidemiology and non-experimental
comparative effectiveness research.
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Randomized controlled trials (RCTs) are considered the gold standard for assessing the
efficacy of medical interventions, including medications, medical procedures, and clinical
strategies. Nevertheless, particularly for research on the prevention of chronic disease, RCTs
are often not feasible because of the size that would be required to address rare outcomes,
timeliness, budget requirements, and ethical constraints [1]. Non-experimental studies of
medical interventions are not subject to these limitations, but have frequently been criticized
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because of their potential for confounding bias [2, 3]. This concern reached a crescendo with
the disparity in estimated effects of postmenopausal hormone therapy on the risk for
cardiovascular events from RCTs and non-experimental studies.[4] These discrepancies
highlighted the need to develop and apply improved methods to reduce bias in non-
experimental studies in which confounding is likely [5].
Rosenbaum and Rubin [6] developed the method of the propensity score (PS) as an
alternative to multivariable outcome models for confounding control in cohort studies. PSs
have become increasingly popular to control for measured confounding in non-experimental
(epidemiologic or observational) studies that assess the outcomes of drugs and medical
interventions [7]. While not generally superior to conventional outcome models [8], PSs
focus on the design of non-experimental studies rather than the analysis [9]. Combined with
the new user design [10], PSs specifically focus on decisions related to initiation of
treatment and hypothetical interventions [11].
By comparing the distribution of PSs between the treated and untreated cohorts, PSs permit
ready assessment to determine whether or not the treated and untreated patients are fully
comparable [12, 13] and identification of patients treated contrary to prediction [14]. Based
on these recent developments, a re-analysis of the data from the Nurses’ Health Study [15]
and an analysis of the Women’s Health Initiative observational study [4] on the effects of
estrogen and progestin therapy on coronary heart disease in postmenopausal women that
followed a new user design and dealt with selection bias after initiation showed results
compatible with the ones from RCTs.
Herein we review the concept of PSs, the implementation of PSs, and specific issues
relevant to non-experimental studies of medical interventions. The aim of the review was to
help clinical researchers understand specific advantages of PSs, to appropriately implement
PSs in research, and to evaluate the studies using PSs from the medical literature. Our focus
was on issues that are relevant for making valid treatment comparisons, and we therefore
start with some general topics that are important to understand the specific benefits of PSs
for medical research.
Variability in treatment decisions
Medical decision making is complex and influenced by many factors. While patient
characteristics (e.g., disease progression, unrelated co-morbidities, co-medications, and life
expectancy) are important determinants of treatment choice, treatment decisions are also
influenced by a wide variety of factors that are largely independent of the patient’s health,
including calendar time, physician training, healthcare setting (including financial
pressures), detailing on the physicians’ side, and various forms of direct-to-consumer
advertising, beliefs (including religion), family, and others (e.g., household help).[16] Note
that some of thesefactors can be measured, while many are either unmeasured or even
unknown.
For non-experimental research, however, the more important distinction is whether or not
factors influencing the treatment decision are independent of the risk for the outcome under
study. Only those factors affecting treatment decisions that also affect the risk for the
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outcome of interest are confounders, and if unaccounted for, lead to biased estimation of
treatment effects. Factors affecting treatment decisions that are unrelated to the outcome of
interest, measured or not, are the factors that allow us to do non-experimental research of
medical interventions. If all the variation in treatments is related to the risk for the outcome,
we are unable to estimate the treatment effect. This setting has been termed “structural
confounding.”[12] In medical research we are often confronted with something in between
these two extremes termed “confounding by indication;” some of the variability in
treatments, but not all of the variability is a function of disease severity (the indication).[5]
Because disease severity is difficult to measure, some have strongly argued against non-
experimental research for intended effects of medical interventions [1, 3, 17]. If all
physicians and their patients would make the same treatment decision based solely on
uniform and reliable measures of disease severity (indication), then we would indeed be
unable to study medical interventions outside of RCTs. When comparing treated to untreated
persons, confounding by indication is often intractable. Fortunately, in actual medical
practice, we often have a choice of interventions and a range of views among physicians and
patients about appropriateness of treatment and willingness to choose it. For example, there
are several long-acting insulins on the market. Guidelines for treatment of persistent asthma
offer a choice of treatments for most of the different stages of severity. Comparing
treatments that are indicated for the same stage of disease progression drastically limits the
potential for confounding by indication. A comparative study of two treatments also
eliminates confounding by frailty that results when comparing patients receiving preventive
treatments with untreated patients [16, 18, 19].
Confounding
Confounding is a mixing of effects (Figure 1).[20] This can be depicted using the following
causal diagram:
A classic example of confounding (by indication) is the estimation of the effects of beta
agonists on asthma mortality. Patients with more severe asthma are more likely to be treated
with beta agonists (at any point in time) and asthma severity is an independent predictor of
asthma mortality. To depict this confounding by indication using purely hypothetical
numbers we have dichotomized the treatment into yes (E=1) or no (E=0) and asthma
severity into severe asthma (X=1) and less severe asthma (X=0)(Figure 2).
Treatment effect heterogeneity
It is reasonable to assume that treatment effects (both intended and unintended) are not the
same in every patient. Good candidates for treatment effect heterogeneity are age (e.g.,
children and older adults), gender, disease severity, co-morbidity (e.g., diabetes), and
comedication (e.g., “polypharmacy”), which are relatively easy to study.
Examples of clinically relevant treatment effect heterogeneity include adjuvant
chemotherapy with oxaliplatin in patients with stage III colon cancer, which has been shown
to improve survival in patients with a median age of 60 years [21], but may not do so in
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patients above age 75 years [22], and the primary prevention of myocardial infarction with
low-dose aspirin in men [23], but not women [24].
Treatment effect heterogeneity has consequences for the estimation of overall treatment
effects. If the effect of treatment with beta agonists is more pronounced in those with severe
asthma, the proportion of patients with severe asthma in the study population will influence
the estimation of any overall treatment effect (Figure 3). The overall treatment effect in the
population will be a weighted average of the treatment effect in those patients with severe
asthma and those patients with less severe asthma. The ability to define the population
studied (e.g., a population in which the prevalence of severe asthma is 20%) becomes
essential, and is a critical component of principled “causal inference”.[25-27] Our focus
herein will be on the relative risk (RR). Homogeneous RRs generally imply treatment effect
heterogeneity on the risk difference scale if the treatment has an effect and vice versa.
Propensity Scores
Theory
The PS is a covariate summary score defined as the individual probability of treatment
(exposure) given (conditional on) all confounders [6]. In our example, 50% of those with
severe asthma receive beta agonists, so every patient with severe asthma will have a PS of
0.5 whether or not the patient was actually treated. While in practice there may be different
covariate patterns that lead to a PS of 0.5, Rosenbaum and Rubin [6] proved that treated and
untreated patients with the same PS value (e.g., treated patients with a PS of 0.5 and
untreated patients with a PS of 0.5) will, on average, have the same distribution of covariates
used to estimate the PS. Thus, by holding the PS constant (conditioning on the PS) treated
and untreated cohorts will tend to be “exchangeable” with respect to the covariates.
Exchangeability, in return, leads to unconfounded estimates of treatment effects because it
removes the arrow from the covariate(s) to the treatment (Figure 1 above). Note that
exchangeability is restricted to measured covariates whose relation with treatment is
correctly modeled in the PS. We therefore need to assume no unmeasured confounding,
which is much more plausible with randomization, another method to obtain
exchangeability.
The ability to control for confounding using PSs is, in general, not different from what we
would achieve by using a more conventional multivariable outcome model [8], but the PS
has some specific advantages outlined below. The PS also allows us to clearly define the
study population in the presence of treatment effect heterogeneity, something that cannot be
achieved using a conventional multivariable outcome model [28]. We will now provide a
non-technical description of PS estimation and implementation.
Estimation
The PS is usually estimated using multivariable logistic regression. The few published direct
comparisons between logistic regression and other methods to estimate the PS (e.g., neural
networks [29]; boosted CART [30, 31]) found that PS performs well in most settings. More
recently, PS estimation methods based on optimizing balance have been proposed [32].
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These are promising, but their performance and causal implications have not yet been
thoroughly assessed. It is thus reasonable to use logistic regression to estimate PSs.
As with any model, mis-specification of the PS can lead to bias. An advantage of PSs is that
we can check the performance of the model by assessing covariate balance across treatment
groups after stratifying, matching, or weighting on the estimated PS (PS implementation
discussed below). If covariate imbalances remain, the PS model can be refined, e.g., by
using less restrictive terms for continuous covariates (e.g., squared or cubic terms, fractional
polynomials, and splines) or by adding interaction terms between covariates.
Although the ability to check covariate balance is a beneficial aspect of PS methods, there is
no agreed-upon best way to check or summarize covariate balance. The vast majority of the
current methods proposed to quantify covariate imbalances do not take the confounding
potential of the remaining imbalances into account. We therefore suggest using the approach
proposed by Lunt et al. [33] that assesses the confounding potential of remaining imbalances
by assessing the change in estimate after controlling for individual covariates in the outcome
model after PS implementation. A change in estimate indicates a remaining imbalance of the
covariate across treatment groups and that the covariate affects the risk for the outcome
independent of treatment. A graphical depiction of the spread of the changes in estimate can
then be used to compare different PS estimation or implementation methods [33].
As in any non-experimental study, the process of variable selection is also important for PS
models. The crux lies in the inability of the data to inform us about causal structures. In fact,
data cannot be analyzed without the researcher imposing a causal structure [34].
Thus far we have depicted the PS as a model predicting treatment based on covariates. We
now need to add an important distinction between the PS and a model intended to optimize
discrimination between treatment groups.[35] Consider in our hypothetical study of beta
agonists outlined above a random selection of the physicians treating patients with asthma
has recently been visited by a detailer making a very compelling argument to treat more
patients with beta agonists irrespective of asthma severity. So, we build the PS based on
asthma severity (and all potential risk factors for asthma mortality, the outcome of interest)
to control for confounding. Should we add the variable “recent detailer visit” to the PS
model? Because the detailer visit leads to increased prescribing irrespective of asthma
severity, it will clearly improve our prediction of treatment with beta agonists, but does this
help with respect to our aim (i.e., to estimate the unconfounded effect of beta agonists on
asthma mortality)? The answer is no, and even worse, to the contrary. Having had a detailer
visit is an “instrumental variable,” i.e., a variable associated with the treatment of interest,
but not affecting the outcome (asthma mortality) other than through its relation with the
treatment (beta agonists).
In medical research, instrumental variables are those that explain variation in treatments, but
are not directly related to the outcome of interest. As outlined above, this is the “good”
variability (e.g., the change in prescribing following the detailer visit). Without such
variability, we would not be able to conduct non-experimental research. By removing
“good” variability, we not only decrease the precision of the estimate [36], but also increase
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the contribution of “bad” variability, i.e., unaccounted for variability in treatments that
affects the risk for the outcome (also called unmeasured confounding) [16, 37]. This issue is
not just academic [38] and the crux lies in the fact that the data will not tell us whether or
not a variable is a confounder or an instrumental variable. Some have argued that it is safer
to err on the side of including variables in the PS [37] or to use automated procedures to
screen hundreds of potential covariates in studies using large automated healthcare databases
[39]. Automated procedures have been shown to improve confounding control in some [39],
but not all settings [40, 41]. They should be implemented with care and considering the
potential for inclusion of instrumental variables.
Implementation
Once the PS is estimated, we can control for this covariate summary score as for any other
continuous covariate using standard epidemiologic techniques, including stratification,
matching, standardization (weighting), and outcome regression modeling. Modeling (adding
the PS to a multivariable outcome model) is the least appealing of these implementation
methods because its validity is dependent on correctly specifying two models (the PS and
the outcome model) and it also does not offer specific advantages of other PS
implementations, as outlined below. We therefore do not recommend implementing the PS
as a continuous covariate in an outcome regression model.
One of the main advantages of the PS is that it provides an easy way to check whether or not
there are some patient characteristics (covariate patterns) that define groups of patients in
whom there is no variability in treatments (i.e., everyone treated or no one treated;Figure 4).
It might be that, following our beta agonists and asthma example, within the group of
patients with mild asthma there is a group of patients with very mild asthma in which no one
is treated with beta agonists. It is easy to see that there are no data to estimate any treatment
effect in this group, unless we make the strong, and likely incorrect assumption that risk of
death and treatment effects in these patients with very mild would be identical to those in the
group of treated patients with mild asthma. While extrapolation of treatment effects to
groups for whom we have no data to estimate the treatment effect may be very sensible in
practice, researchers should at least be aware of such extrapolations. PSs allow us to limit
model extrapolation by excluding patient groups from the analysis in whom no treatment
effect can be estimated because all patients are either never (untreated with PS lower than
the lowest PS in the treated) or always treated (treated with higher PS than the highest PS in
the untreated). Trimming (excluding) non-overlap regions of PS should be the default prior
to any PS implementation. The untrimmed and trimmed populations need to be compared;
however, because trimming patients with very mild asthma (our example) leads to a focused
inference that is not generalizable to all asthmatics.
Stratification of continuous covariates into equal-sized strata (percentiles), estimation of the
treatment effect within these percentiles, and combining the stratum-specific estimates using
a weighted average (e.g., Mantel-Haenszel; MH [42]) is a well-established method to control
for confounding by any continuous covariate, including the PS. Trimming of non-overlap
should be done before creating percentiles. Depending on the number and distribution of
outcomes, it is often possible to use 10 strata (deciles) rather than the “usual” five strata
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(quintiles), thus reducing residual confounding within strata. Because most methods to
average stratum-specific estimates assume uniform treatment effects across strata, it is
important to estimate and evaluate the stratum-specific treatment effect estimates before
combining the stratum-specific treatment effect estimates into an overall estimate. Using our
numerical example above (Figure 2), stratifying on the PS will be the same as stratifying on
asthma severity; there are only two distinct PS values (PS=0.5 for all those with X=1 and
PS=0.1 for all those with X=0). Because the treatment effect is uniform (RR=0.5 in both PS
strata) we know that any weighted average, including the MH estimate, of the unconfounded
effect of beta agonists on asthma mortality in our cohort will yield a RR=0.5.
Matching on specific covariates in cohort studies removes confounding by the matching
variable(s) and has been used extensively in epidemiologic research prior to the widespread
availability of multivariable models [43]. Matching on a large number of covariates quickly
becomes intractable; however, and summary scores, including the PS, were originally
proposed to overcome this limitation [44, 45]. In theory, the implementation is
straightforward; for every treated patient we find a single or multiple untreated patients with
the same PS (or nearly the same PS, based on a pre-determined caliper) and put the matched
pair aside. We then repeat this step until we acquire all of the treated patients matched to the
same number of untreated patients (a selection of all the untreated patients). In practice,
however, this is more complicated because we may not find an untreated match for every
treated patient. The ability to find matches for all treated patients is a complex function of
the overall prevalence of the treatment in the population, the separation of the PS
distribution in treated and untreated patients, and the width of the PS caliper used [33, 46].
There is a general trade-off between residual confounding (minimized by narrow calipers)
and finding matches (maximized by wide calipers). Various matching algorithms are
available and the comparative performance has been assessed using simulations [47]. We
have often used a greedy matching algorithm [48] and this has been shown to perform well
in both actual studies and simulations [47]. It is important to report the number or proportion
of treated patients that could be matched. Higher proportions are preferred. Note that the
proportion of untreated patients that could be matched, and therefore the overall number of
patients matched, is not relevant here.
Standardization is a way to validly summarize treatment effects in the presence of treatment
effect heterogeneity. Note that matching implicitly standardizes the estimate to the treated
population. “Standardizing” to the treated population can also be achieved using
standardized mortality/morbidity ratio (SMR) weights [49] (the quotes around
“standardizing” are due to a technicality: we can only standardize on categories of variables,
whereas weighting actually allows us to include continuous variables and is thus more
flexible). These weights create a pseudo-population of the untreated, which has the same
covariate distribution as the treated. While every treated person receives a weight of 1 (i.e.,
the observed), every untreated person is weighted by the PS odds [PS/(1-PS)]:
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We now use our numerical examples presented in Figures 2 and 3 to illustrate PS
implementation to estimate the average treatment effect in the treated. For clarity, we retain
the single, dichotomous covariate example in which there is no difference between
controlling for this single covariate and the PS. In practice, however, the PS will be a
summary score of multiple covariates reduced into a single covariate, which allows us to
efficiently implement all that follows rather than doing this for each and every covariate
separately. PS matching (in expectation) and SMR weighting will lead to the numbers
presented in Figure 5 and an unconfounded RR=0.5 in the collapsed table. The prevalence of
treatment, and thus the estimated PS, is 0.1 in those with X=0 and 0.5 in those with X=1.
Another typical standard is the overall population of the treated and untreated. This can be
achieved by implementing the PS using inverse probability of treatment weights (IPTW). In
settings with an active comparator, estimating the treatment effect in the entire population
obviates the need to determine which treatment to identify as treated and untreated in PS
matching and SMR weighting. IPTW creates a pseudo-population of both the treated and the
untreated, which has the same covariate distribution as the overall population of treated and
untreated. Every person is weighted by the inverse of the probability of receiving the
treatment actually received [the PS in the treated and (1-PS) in the untreated]. Stabilizing
these weights by the marginal overall prevalence of the treatment actually received has
specific advantages that are beyond the scope of this review.[27] The actual stabilized IPTW
weights are easily implemented based on the estimated PS, as follows:
In our numerical example, the marginal prevalence of treatment, PE, is 0.18 (Figure 2).
Using our estimated PS values would lead to the weights, and on average, the numbers
presented in Figure 6 and again to an unconfounded RR=0.5 in the collapsed table.
In our above numerical example, all PS implementation methods led to the same
unconfounded treatment effect estimate (RR=0.5) because the treatment effect is uniform.
The results for our numerical example with heterogeneous treatment effects, as introduced in
Figure 3, are shown below in Figure 7. As can be seen, the treatment effect in the treated (PS
matching or SMR) is more pronounced than the treatment effect in the population (IPTW).
Note that all estimates are unconfounded. The difference between the estimates from MH,
PS matching or SMR, and IPTW is due to the fact that the prevalence of severe asthma, in
which the treatment is effective, is higher in treated patients (55%) than the entire population
of treated and untreated (20%). The MH estimate is not valid in this setting because it
assumes uniform effects and the MH weighted average does not pertain to any defined
population; the weights are entirely chosen to minimize variance and result in relying
heavily on the stratum with severe asthma (X=1) because most of the events are observed in
this stratum (w=0.93).
PS matching, the SMR, and IPTW result in so-called causal contrasts because the population
of interest is clearly defined. The data (Figs. 3, 7) suggest that there is no value to use of
beta agonists in those with mild asthma (X=0). With such marked heterogeneity, presenting
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treatment effects stratified by asthma severity would be essential and any average treatment
effect would have uncertain utility for treatment decisions in practice.[50]
PS matching and SMR weights allow us to estimate the average treatment effect in the
treated, i.e., in patients with the same distribution of covariates as the one actually observed
in the treated. The average treatment effect in the treated answers the question, “What would
have happened if those actually treated had not received treatment?” In our experience,
matching or SMR weighting are preferable when the comparator group is either untreated or
not well-defined, as is often the case in pharmacoepidemiology (although active referent
groups are increasingly used in settings, such as evaluation of comparative effectiveness).
Estimating the treatment effect in a population with a reasonably high prevalence of the
indication for treatment reduces the potential for violations of positivity that we would likely
encounter with IPTW in such a setting.
With an active comparator (a treatment alternative rather than untreated), the indication can
often be assumed to be equally prevalent in both treatment groups, thus limiting the potential
for violations of positivity. IPTW will often make sense with an active comparator, allowing
us to estimate the average treatment effect in the entire population. This answers the
question of what would have happened if everyone had been treated with “A” versus what
would have happened if everyone had been treated with “B,” the same question that is asked
in an RCT [51]. Note that being able to make these causal contrasts is dependent on
predicting treatment based on relevant covariates, i.e., the estimation of the PS [6].
In practice, the distribution of weights needs to be carefully checked for both SMR
weighting and IPTW because some patients, i.e., those treated contrary to prediction, receive
large weights (are “replicated” or “cloned” many times), and thus can become highly
influential. For IPTW a rule of thumb for well-behaved weights (“no problem”) would be a
mean stabilized weight close to 1.0 and a maximum stabilized weight of < 10 [52]. Thus far,
no similar rule of thumb has been evaluated for SMR weighting, but in the meantime it
would seem reasonable to also use weights ≥ 10 as a sign for concern. If weights > 10 are
observed, researchers should check whether or not instrumental variables can be excluded
from the PS model and perform sensitivity analyses involving additional trimming (see
below).
Trimming
Thus far we have assumed no unmeasured confounding. While this assumption is necessary
to estimate treatment effects using any adjustment method, in reality the assumption of no
unmeasured confounding will often be violated to some extent. Some patients that have the
indication for treatment (e.g., because they have severe asthma) may be too frail to receive
the treatment. Because frailty is a concept that is difficult to measure, it can lead to
substantial bias in non-experimental studies of medical interventions compared with no
intervention [19, 53]. Because the PS focuses on treatment decisions, it allows us to identify
patients treated contrary to prediction in whom confounding, e.g., by frailty, may be most
pronounced. These are the untreated patients with the highest PS and the treated patients
with the lowest PS (Figure 8). Under this assumption, trimming increasing proportions of
those at both ends of the overlapping PS distribution has been shown to reduce unmeasured
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confounding [14]. It is important to use a percentage (e.g., 1%, 2.5%, and 5%) of those
treated contrary to prediction to derive cut-points for trimming only. Once these cut-point
have been established, both treated and untreated below the lower and above the higher cut-
points need to be excluded from the analysis to avoid introducing bias. The choice of cut-
points will depend on the specific setting and the change in the treatment effect estimate
across various cut-points will be more informative than any specific value, and thus results
from the whole range of trimming should be reported (in addition to the number of patients
and events trimmed by treatment group). According to our experience, trimming may be
especially important with IPTW, but we recommend routinely performing a sensitivity
analysis based on trimming for any PS implementation method. As with any sensitivity
analysis, transparency is important and untrimmed results need to always be presented
together with trimmed results. As with trimming non-overlap, as described above, additional
trimming within the overlap population leads to a more focused inference that is no longer
generalizable to the treated or the entire population.
Recommendations
PSs are an alternative to multivariable outcome models to control for measured
confounding. Compared with multivariable outcome models, PSs have specific advantages,
including identification of barriers for treatment (e.g., older adults), the implicit
consideration of relative timing of covariates and treatment (covariate should precede
treatment initiation), the ability to present the resulting balance of covariates which is
needed to remove confounding (exchangeability), the trimming of patients outside of a
common range of covariates in whom we have no data to estimate the treatment effect, the
ability to estimate causal contrasts in the presence of treatment effect heterogeneity, and the
ability to control for many covariates in settings with many treated and rare outcomes.[11]
We have focused on causal contrasts in the presence of heterogeneous treatment effects
because we think that this issue is not well-recognized by clinical researchers. Treatment
effects are likely to be heterogeneous across age, gender, co-morbidities, and co-
medications, and PSs as implemented using matching or weighting allow us to estimate
valid overall treatment effects in such settings. With strong treatment effect heterogeneity
across the PS, research should attempt to pinpoint actual covariates leading to heterogeneity
because identification of such patient groups might be relevant for clinical practice. For
example, the data in Figures 3 and 7 raise the possibility that treatment has no benefit in
those with X=0, but has an even greater benefit in those with X=1 than the estimated overall
treatment effect. This might spur further evaluation of subgroup-specific effects and
consideration of shifts in the population targeted for treatment. With an unexposed
comparison group, estimating the treatment effect in the treated (PS matching or SMR
weighting) will often be preferred because we would rarely want to treat everyone who is
currently not treated. In the setting of an active comparator (e.g., comparative effectiveness
research), estimating the treatment effect in the entire population (IPTW) will often make
most sense because we are focusing on treatment choice after the treatment decision per se
has been made. Heterogeneous treatment effects can also be due to unmeasured confounding
concentrated in those treated contrary to prediction. Sensitivity analyses based on PSs allow
us to assess the potential for and reduce such unmeasured confounding.
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Figure 1. Causal Diagram for Confounding
Both arrows need to be present to cause confounding. Removing one of the arrows removes
confounding. This leads to essentially two general ways to control for confounding; we can
remove the effect of the confounder on treatment (PS methods) or we can condition on the
effect of the confounder on the outcome (outcome modeling). Both are dependent on having
a good measure of the confounder available to the researcher.
Stürmer et al. Page 14






















Figure 2. Numerical Example for Confounding and Uniform Treatment Effects
The treatment with beta agonists (E) reduces asthma mortality (Y) in both patients with
severe (X=1; RR=0.5) and less severe (X=0; RR=0.5) asthma, but the crude relative risk
shows that beta agonists are associated with increased mortality (RR=1.74). Note that
patients with severe asthma (X=1) are more likely to be treated with beta agonists and more
likely to die, which leads to the confounding in the crude (unadjusted) table.
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Figure 3. Numerical Example for Confounding and Treatment Effect Heterogeneity
Hypothetical example of beta agonists and asthma mortality with treatment effect
heterogeneity (in addition to confounding, it is possible to construct scenarios without
confounding [28], but such a scenario would be implausible for our asthma example); the
treatment is not effective in preventing asthma mortality in those with less severe asthma
(X=0; RR=1), while being very effective in those with severe asthma (X=1; RR=0.25).
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Schematic for Non-Overlap in Propensity Score Distributions – Exclusion (Trimming) of
Non-Overlap (Shaded Areas) Reduces Model Extrapolation to Covariate Patterns in Which
No Treatment Comparison Can Be Made (“Non-Positivity”)
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Figure 5. Numerical Example for PS Matching and SMR Weighting
We present the SMR weights (w) separately for all exposure (E) and covariate (X) patterns;
in a real study, they would be calculated based on exposure status and the estimated PS.
Note that in our numerical example we can match all those treated and for matching and
SMR weighting, the prevalence of severe asthma (X=1) in the untreated (1000/1800=0.55)
is the same as the prevalence of severe asthma in the treated (1000/1800 – see Figure 2). The
fact that the size of the study population is reduced only affects the precision of the estimate,
but not its validity nor its causal interpretation.
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Figure 6. Numerical Example for Inverse Probability of Treatment Weighting
All observed N and numbers of events (Y=1) in Figure 2 are multiplied by the (stabilized)
IPTW weights leading to the pseudo-populations depicted in the stratified tables above,
which are then collapsed into the table on the right without matching. Note that those treated
contrary to prediction (E=1 when X=0) are up-weighted (weight > 1), while those treated
according to prediction (E=0 when X=0 and E=1 when X=1) are down-weighted to achieve
covariate balance across treatment groups. The distribution of severe asthma (X=1) in
treated and untreated is now the same as in the total population (prevalence of 20%; Figure
2).
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Numerical Example for Mantel Haenszel (Invalid, for Comparison Only), Standardized
Mortality/Morbidity Ratio (SMR), PS Matching, and SMR Weighting, and Inverse
Probability of Treatment Weighting in the Presence of Treatment Effect Heterogeneity
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Schematic for Trimming at the Ends of the (Overlapping) Propensity Score Distribution
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